New lipid lowering agents

• Published in: Revista medíca de Chile Vol. 142; no. 7; pp. 880 - 888
• Main Authors: Cuevas, Ada, Farías, María Magdalena, Alonso, Rodrigo
• Format: Journal Article
• Language: Spanish
• Published: Chile 01.07.2014
• Subjects: Antibodies, Monoclonal - therapeutic use; Anticholesteremic Agents - therapeutic use; Benzimidazoles - therapeutic use; Clinical Trials as Topic; Humans; Hypercholesterolemia - drug therapy; Oligonucleotides - therapeutic use; Proprotein Convertase 9; Proprotein Convertases - therapeutic use; Serine Endopeptidases - therapeutic use
• ISSN: 0717-6163
• DOI: 10.4067/S0034-98872014000700008

Statins are the preferred treatment for hypercholesterolemia and several studies have demonstrated their long-term safety and efficacy in reducing cardiovascular morbidity and mortality. However, in some cases of severe hypercholesterolemia such as homozygous and heterozygous familial hypercholesterolemia or statin intolerant patients, statins can be less efficient. In recent years, new lipid-lowering agents with novel mechanisms of action have been developed to reduce LDL-cholesterol in patients with severe hypercholesterolemia, associated or not to conventional lipid-lowering therapy. These therapies include microsomal transfer protein inhibitor (Lomitapide), antisense oligonucleotide to Apo B100 (Mipomersen) and monoclonal antibodies against Proprotein convertase subtilisin/kexin type 9 (PCSK9). Different studies have shown the great effectiveness of these new therapies. Short-term studies confirmed their adequate security profile, especially in patients with homozygous familiar hypercholesterolemia or severe hypercholesterolemia. Some of these agents have been also tested in statin-intolerant patients. However, long-term studies are needed to evaluate their safety, effectiveness and impact on cardiovascular risk reduction.